Clinical Trials Logo
  1. Home
  2. Colorectal Liver Metastases
  3. NCT05877001

The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases

Colorectal Liver Metastases Clinical Trial

Official title:
An Open Label, Single-center Study on the Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib in Patients With Advanced Treated Colorectal Liver Metastases

Clinical Trial Summary

Tislelizumab is an anti-PD-1 monoclonal antibody with high binding affinity for PD-1 and with minimized Fcγ receptor binding on macrophages. Regorafenib has been approved in mCRC by CFDA. Hepatic arterial infusion chemotherapy has a high local control rate for liver metastases. NCCN guidelines and several expert consensus recommend that regional hepatic arterial infusion chemotherapy can be considered as a "rescue treatment" for patients with colorectal cancer liver metastases who fail to receive first-line or second-line systemic chemotherapy, which can significantly prolong the overall survival of patients.

Clinical Trial Description

The investigators aimed to evaluated the safety and efficacy of HAIC combined with Tislelizumab and Regorafenib in patients with advanced treated colorectal liver metastases. This study is a prospective, open label, single-center clinical study and the sample size is 20. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05877001
Study type Interventional
Source Peking University Cancer Hospital & Institute
Contact Xu Zhu, MD
Phone +86-10-88196001
Email drzhuxu@163.com
Status Recruiting
Phase Phase 2
Start date May 30, 2023
Completion date March 1, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT01255007 - Comparison of Primovist-enhanced MRI, Diffusion Weighted MRI and Multidetector CT of Colorectal Liver Metastases N/A
Completed NCT00779272 - Impact of Preoperative Chemotherapy on Complications and Regeneration After Resection of Colorectal Liver Metastases N/A
Active, not recruiting NCT00797251 - Anatomical Right Posterior Sectionectomy of the Liver by IOUS-Guided Finger Compression N/A
Recruiting NCT06045286 - High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM Phase 1
Recruiting NCT04870879 - Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors N/A
Completed NCT01799044 - Pilot-study: Non-thermal Ablation Using Irreversible Electroporation to Treat Colorectal Liver Metastases Phase 1
Terminated NCT00508872 - Folfox-B Study for Patients With Colorectal Liver Metastases Phase 2
Completed NCT02082782 - Efficacy of Irreversible Electroporation (IRE) for Central Colorectal Liver Metastases Phase 2
Completed NCT00942292 - The Effect of Fish Oils on Human Hepatic Colorectal Metastases Phase 2
Recruiting NCT01191632 - Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Low Dose Radiation in Colorectal Liver Metastases Phase 1/Phase 2
Completed NCT00119899 - Utility of FDG-PET Scan on the Selection of Patients for Resection of Hepatic Colorectal Metastases Phase 3
Completed NCT00184834 - Quality of Life and Liver Metastases N/A
Completed NCT00557557 - Safety Study of Oxaliplatin and 5-fluorouracil Followed by FUDR for Unresectable Colorectal Liver Metastases Phase 1
Recruiting NCT05468593 - Patient Outcomes After Hepatic Artery Infusion Pump Placement
Completed NCT02615665 - Intratumoral CD3+ and NKp46+ Cells in Colorectal Liver Metastases N/A
Terminated NCT01318447 - CyberKnife® for Hepatic Metastases From Colorectal Cancer Phase 2
Completed NCT00885950 - Prevention of the Hepatic Sinusoidal Obstruction Syndrome by Means of Anticoagulants N/A
Completed NCT02331641 - Multiple Minor Hepatectomies Versus Major or Extended Hepatectomies for Colorectal Liver Metastases. N/A
Completed NCT00600522 - Alternative Surgical Policy for Central Liver Tumors N/A
Recruiting NCT05265169 - Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM) N/A